Review Article

Hypercoagulability as a Cause of Stroke in Adults

Authors: Marc J. Kahn, MD

Abstract

Arterial hypercoagulability can lead to cerebrovascular disease. Common causes of venous thromboembolism, including factor V Leiden, the prothrombin 20210 mutation, deficiencies of proteins C and S, and antithrombin deficiency are not likely to be associated with stroke. Rather, polymorphisms in fibrinogen, the factor XIII gene, and platelet glycoproteins are congenital abnormalities that have been associated with stroke. Similarly, the acquired conditions, lupus anticoagulants, and heparin-induced thrombocytopenia have a strong association with cerebrovascular disease. This article reviews arterial hypercoagulability as a cause of stroke in adults and identifies an appropriate hypercoagulability workup for patients with idiopathic stroke.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

  1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004–1008.
  2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–67.
  3. Zunker P, Hohenstein C, Plendl HJ, Zeller JA, Caso V, Georgiadis D, et al. Activated protein C resistance and acute ischaemic stroke: Relation to stroke causation and age. J Neurol 2001; 248: 701–704.
  4. Smiles AM, Jenny NS, Tang Z, Arnold A, Cushman M, Tracy RP. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: Results from the cardiovascular health study. Thromb Haemost 2002; 87: 614–621.
  5. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001; 32: 1793–1799.
  6. Amiri M, Schmidley JW, Fink LM, Nazarian SM. Is testing for inherited coagulation inhibitor deficiencies in young stroke patients worthwhile? Clin Neurol Neurosurg 2000; 102: 219–222.
  7. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501–505.
  8. Kant JA, Fornace AJ Jr, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: Gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A 1985; 82: 2344–2348.
  9. Schmidt H, Schmidt R, Niederkorn K, Horner S, Becsagh P, Reinhart B, et al. Beta-fibrinogen gene polymorphism (C148→T) is associated with carotid atherosclerosis: Results of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol 1998; 18: 487–492.
  10. Nishiuma S, Kario K, Yakushijin K, Maeda M, Murai R, Matsuo T, et al. Genetic variation in the promoter region of the &bgr;-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis 1998; 9: 373–379.
  11. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906–908.CattoAJ
  12. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu: A novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813–816.
  13. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol 1994; 31: 229–239.RuggeriZMNew insights into the mechanisms of platelet adhesion and aggregation
  14. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090–1094.
  15. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385–388.
  16. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol 1998; 18: 1124–1131.
  17. Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GpIb/IX) and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 1997; 28: 1392–1395.
  18. Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, et al. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 1998; 92: 2771–2776.
  19. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997; 277: 1775–1781.
  20. Brattstrom L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997; 96: 3805–3807.
  21. Lechner K. Lupus anticoagulants and thrombosis. Thromb Haemost 1987; 58: 525(abstract).
  22. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–1547.
  23. Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259: 550–554.
  24. Rosove MH, Brewer PM, Runge A, Hirji K. Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids. Am J Hematol 1989; 32: 148–149.
  25. Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol 1989; 16: 614–617.
  26. Zielinska J, Ryglewicz D, Wierzchowska E, Lechowitz W, Hier DB, Czlonkowska A. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol Res 1999; 21: 653–657.
  27. Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: A prospective follow-up study. Neuroepidemiology 2002; 21: 93–99.
  28. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, et al. &bgr;(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: The Honolulu Heart Program. Stroke 2001; 32: 1701–1706.
  29. Fiallo P, Tomasina C, Clapasson A, Cardo PP. Antibodies to &bgr;(2)-glycoprotein I in ischemic stroke. Cerebrovasc Dis 2000; 10: 293–297.
  30. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95–96(letter).
  31. Ramirez-Lassepas M, Cipolle RJ, Rodvold KA, Seifert RD, Strand L, Taddeini L, et al. Heparin-induced thrombocytopenia in patients with cerebrovascular ischemic disease. Neurology 1984; 34: 736–740.
  32. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804–812.
  33. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111–128.
  34. Aronow WS, Ahn C, Schoenfeld MR. Association between plasma homocysteine and extracranial carotid arterial disease in older persons. Am J Cardiol 1997; 79: 1432–1433.
  35. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395–1398.
  36. Duell PB, Malinow MR. Homocysteine: An important risk factor for atherosclerotic vascular disease. Curr Opin Lipidol 1997; 8: 28–34.